HighTower Advisors LLC Boosts Stock Holdings in Immuneering Corporation $IMRX

HighTower Advisors LLC grew its position in Immuneering Corporation (NASDAQ:IMRX) by 17.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 83,960 shares of the company’s stock after acquiring an additional 12,600 shares during the period. HighTower Advisors LLC’s holdings in Immuneering were worth $128,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Tang Capital Management LLC acquired a new position in shares of Immuneering in the fourth quarter worth about $27,000. First Manhattan CO. LLC. acquired a new position in shares of Immuneering in the fourth quarter worth about $71,000. Two Sigma Investments LP raised its position in shares of Immuneering by 25.0% in the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after acquiring an additional 10,126 shares during the period. Bridgeway Capital Management LLC raised its position in shares of Immuneering by 77.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock worth $113,000 after acquiring an additional 22,400 shares during the period. Finally, Southport Management L.L.C. raised its position in shares of Immuneering by 4.9% in the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock worth $473,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 67.65% of the company’s stock.

Insider Activity at Immuneering

In other Immuneering news, Director Thomas J. Schall acquired 9,500 shares of the company’s stock in a transaction that occurred on Friday, June 27th. The stock was bought at an average price of $3.66 per share, with a total value of $34,770.00. Following the purchase, the director owned 52,885 shares in the company, valued at approximately $193,559.10. The trade was a 21.90% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter Feinberg acquired 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 18th. The shares were acquired at an average cost of $2.53 per share, with a total value of $63,250.00. Following the purchase, the director owned 136,766 shares in the company, valued at $346,017.98. This represents a 22.37% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 127,507 shares of company stock valued at $334,318. Corporate insiders own 22.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on IMRX. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Immuneering in a research report on Tuesday, August 26th. Chardan Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a research report on Thursday, August 14th. Finally, Mizuho boosted their target price on shares of Immuneering from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 18th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.00.

Immuneering Stock Up 0.9%

Shares of IMRX opened at $5.51 on Friday. Immuneering Corporation has a 52-week low of $1.10 and a 52-week high of $6.35. The firm’s fifty day moving average is $4.16 and its two-hundred day moving average is $2.52. The stock has a market cap of $200.12 million, a PE ratio of -2.92 and a beta of 0.43.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). As a group, research analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current year.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.